Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Stomach Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Carcinoma, Hepatocellular 6Adenocarcinoma 6Neoplasms 5Lung Neoplasms 4Colorectal Neoplasms 4Colonic Neoplasms 4Breast Neoplasms 4Urethral Neoplasms 3Rectal Neoplasms 3Neoplasm Metastasis 3Liver Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Ureteral Neoplasms 2Solid Tumors 2Sarcoma 2Non-small Cell Lung Cancer Metastatic 2Malignant Solid Tumor 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Biliary Tract Neoplasms 2Thymoma 1Solid Tumor 1Sarcoma, Synovial 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

ulixertinib 1tislelizumab 1talazoparib 1serabelisib 1sapanisertib 1pembrolizumab 1olaparib 1mirdametinib 1lenvatinib 1erdafitinib 1crenigacestat 1atezolizumab 1Ramucirumab 1Paclitaxel 1PM 01183 1Injections 1IFL protocol 1Gemcitabine 1Bosentan 1BID protein, human 1Appointments and Schedules 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Solid Tumor × Ramucirumab × Clear all
NCT04557384 2023-02-27

A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Terminated
3 enrolled 9 charts
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡